Translate
Text Highlighter

Bookmark

PDF

Share

Report a problem
AMICUS AI
Citation Codes
Equivalent Citations
citation codes
Case Number
Advocates
Judges
Acts
  • Order 39 Rules 1 and 2 and Section 151 of the Code of Civil Procedure
  • sub-rule (9) (a) of Rule 65 of the Drugs and Cosmetics Rules, 1945
  • Sub-rule (11) of Rule 65
Are you a practicing lawyer?
Enhance your digital presence and reach by creating a Casemine profile.
Upload pleading to use the new AI search
Cites
Cited by
Citation Codes
Equivalent Citations
citation codes
Case Number
Advocates
Judges
Acts
  • Order 39 Rules 1 and 2 and Section 151 of the Code of Civil Procedure
  • sub-rule (9) (a) of Rule 65 of the Drugs and Cosmetics Rules, 1945
  • Sub-rule (11) of Rule 65
Smart Summary

Factual and Procedural Background

The plaintiff, E.R. Squibb & Sons Inc., filed a suit against the defendant, Curewel (India) Ltd., seeking a permanent injunction restraining the defendant from selling its product under the brand name "Curechlor" or any deceptively similar mark to the plaintiff's registered trade mark "Reclor" in relation to the pharmaceutical preparation Chloramphenicol. Along with the suit, the plaintiff moved an application under Order 39 Rules 1 and 2 and Section 151 of the Code of Civil Procedure for a temporary injunction until the suit's decision.

The plaintiff's pleaded facts include: sale of its product under the trade mark "Reclor" in India since 1971 through registered users (Karamchand Premchand Pvt. Ltd. and Sarabhai Chemicals Ltd.), transfer to Elscope Pvt. Ltd. from March 1, 1977; registration of the trade mark "Reclor" in India on May 4, 1966 for medicinal and pharmaceutical preparations; and discovery in October 1984 that the defendant was selling Chloramphenicol capsules under the name "Curechlor." The plaintiff alleged that "Curechlor" is deceptively similar (visually and phonetically) to "Reclor" and that druggists, chemists or nurses might mistakenly supply or administer "Curechlor" when "Reclor" is prescribed.

Procedurally, the matter before the court was the plaintiff's interlocutory application for an interim injunction. The judge heard submissions and evidence relevant to that application. The court dismissed the interlocutory application. The file records: Suit No. 2152/85; parties were directed to appear before the Deputy Registrar on March 18, 1986 for admission/denial of documents; the suit was listed before the Court on May 26, 1986 for framing of issues; and the court's order concludes "I.A. dismissed."

Legal Issues Presented

  1. Whether the adoption of the trade mark "Curechlor" by the defendant for its product containing Chloramphenicol amounts to infringement/passing off or otherwise to a deceptive similarity actionable in respect of pharmaceutical preparations.
  2. Whether the plaintiff demonstrated a prima facie case and a likelihood of ultimate success sufficient to justify a temporary (interlocutory) injunction restraining the defendant from using "Curechlor" pending trial.

Arguments of the Parties

Plaintiff's Arguments

  • The plaintiff has been selling Chloramphenicol under the trade mark "Reclor" in India since 1971 and holds a registration for "Reclor" dated May 4, 1966 for medicinal and pharmaceutical preparations.
  • The defendant adopted the mark "Curechlor" by adding "Cu" at the beginning and an "h" after the "c" of "Reclor," resulting in a mark visually and phonetically deceptively similar to "Reclor."
  • There is a likelihood of confusion: druggists and chemists might supply "Curechlor" mistakenly when "Reclor" is prescribed; even trained nurses might be misled into giving "Curechlor" in place of "Reclor."
  • The plaintiff placed two cash memos on record relating to sales of "Curechlor." The plaintiff's counsel cited authorities (e.g., Kemp & Co. Ltd. v. Cadilla Laboratories Pvt. Ltd.) in support of the contention that "Curechlor" is deceptively similar to "Reclor."

Defendant's Arguments

  • The defendant relied on case law (including the Supreme Court decision in F. Hoffiman-La Roche v. Geoffrey Manners and various English and Indian authorities) to submit that the question of deceptive similarity must be assessed having regard to the class of goods involved; for medicinal preparations that are typically supplied on prescription, chances of confusion are remote.
  • The defendant's trading style is Curewel (India) Ltd., and the defendant adopted the prefix "Cure" from its trading style and the element "chlor" from the drug "Chloramphenicol," which is a bona fide and common pharmaceutical naming practice.
  • There was no allegation (or material placed on record) that the defendant acted dishonestly in adopting the mark "Curechlor" or that any specific instance of confusion had occurred; records (price list and cash memos) show prescription-based sale practices and multiple product names by the defendant beginning with "Cure," supporting bona fides.

Table of Precedents Cited

Precedent Rule or Principle Cited For Application by the Court
F. Hoffiman-La Roche & Co. Ltd. v. Geoffrey Manners and Co. Private Ltd., AIR 1970 S.C. 2062 That the question of deceptive similarity must be decided on the basis of the class of goods to which the trademarks apply; for medicinal goods typically obtained on prescription, the likelihood of confusion is remote; in that case "Dropovit" was held not deceptively similar to "Protovit." The court adopted this principle and applied it to the present dispute, assessing deceptive similarity in the context of medicinal preparations dispensed on prescription.
Re: Bayer Products, Ltd.'s Application, (1947) 2 All E.R. 188 English authority relating to pharmaceutical preparations; cited among cases illustrating the approach to trademarks in pharmaceuticals. Cited by the defendant's counsel as part of a body of authorities supporting the view that assessment depends on class of goods; the court noted that these English decisions took a similar approach to Hoffmann-La Roche.
Geigy A.G v. Chelsea Drug and Chemical Company Ltd., (1966) RPC 64 English authority relating to pharmaceutical trademarks; referenced for approach to pharmaceutical cases. Referred to by defendant's counsel; the court recorded that such judgments align with the Hoffmann-La Roche principle and applied that contextual approach.
Indo-Pharma Pharmaceutical Works Pvt. Ltd. v. Farbenfabriken Bayer Ag., (1975) RPC 545 Authority on pharmaceutical trademark disputes; part of the group of cases cited to show consistent approach in pharmaceutical matters. Included among authorities relied on by defendant's counsel; court noted this line of cases supports the contextual test adopted from Hoffmann-La Roche.
Stadmed Pvt. Ltd., Calcutta v. Hind Chemicals, Kanpur, AIR 1965 Punjab 17 Indian case law referred to in the context of pharmaceutical trademark disputes. Referred to by the defendant's counsel as part of a series of decisions dealing with pharmaceutical preparations; court treated it as consistent with the Hoffmann-La Roche approach.
Mount Mettur Pharmaceuticals (P) Ltd. v. Dr. A. Wander, AIR 1977 Madras 105 Indian authority concerning trademarks in the pharmaceutical field. Cited by defendant's counsel; the court noted it formed part of the consistent jurisprudence supporting evaluation of deceptive similarity in context of pharmaceutical goods.
Chemical Industrial and Pharmaceutical Laboratories Ltd. v. A. Wulfing & another, (1979) 3 IPLR 193 (Bom. HC) Bombay High Court decision on trademarks in pharmaceuticals; cited to illustrate the approach in pharmaceutical cases. Referred to by defendant's counsel; the court recorded this as one of several decisions consistent with the Hoffmann-La Roche test and applied that reasoning.
Kemp & Co. Ltd. v. Cadilla Laboratories Private Limited Cited by the plaintiff; in that case the court granted a temporary injunction where there was very high (99%) phonetic similarity between "Campicillin" and "Kempsillin." The court considered this authority but distinguished it on facts, noting that the level of phonetic similarity in Kemp is not present between "Reclor" and "Curechlor."
Standard Pharmaceuticals Limited v. U.P. Drug Pvt. Ltd., 1980 IPLR 117 Authority where "Winotone" was held to infringe "Vintone" for medicinal preparations; the products there were tonics and not Schedule H drugs. The court distinguished this case on the ground that the products there were tonics (not Schedule H drugs) and thus the circumstances differed from the present Schedule H pharmaceutical context.

Court's Reasoning and Analysis

The court's analysis proceeded by applying the principle, drawn from F. Hoffiman-La Roche and related authorities, that deceptive similarity must be assessed in light of the class of goods to which the trademarks relate. The judge emphasized that medicinal and pharmaceutical preparations, especially those that are dispensed on prescription, present a distinct factual matrix for the assessment of confusion.

First, the court compared the marks visually and phonetically. It found that the marks are "obviously not similar visually" because the defendant's mark begins with "Cu" preceding the entirety of "Reclor" and includes an added "h" after the "c." Phonetically the court also found "a distinct dissimilarity" between "Reclor" and "Curechlor" (the opinion records the defendant's mark as "Curechlor" and the plaintiff's mark as "Reclor"). The court expressly rejected the plaintiff's submission that the "cu" might be spoken feebly or be inaudible and thereby cause confusion.

Second, the court evaluated the context of sale and regulatory safeguards: Chloramphenicol is a Schedule H drug. The court cited sub-rule (9)(a) of Rule 65 and sub-rule (11) of Rule 65 of the Drugs and Cosmetics Rules, 1945, which restrict sale of Schedule H drugs to prescription-only distribution and impose requirements on dispensing chemists (including qualifications). The court reasoned that these restrictions and safeguards mean that chemists—who must be qualified and who dispense only on prescription—are unlikely to be confused by the defendant's trademark when selling the plaintiff's product.

Third, the court considered evidence of bona fides and user practices: the defendant's trading name Curewel and its price list (effective July 1, 1985) show multiple product names beginning with "Cure," suggesting that "Cure" is a customary prefix in the defendant's branding; the defendant's explanation was that "Cure" came from the trading style and "chlor" from the product (Chloramphenicol). The court noted that the plaintiff had not alleged or placed material on record demonstrating dishonest adoption by the defendant.

Fourth, the court observed that the plaintiff did not place any material on record to prima facie show that any particular person (ordinary customer or chemist) was actually misled into taking the defendant's product as that of the plaintiff. The two cash memos produced by the plaintiff showed the presence of prescribing doctors' names and indicated sale on prescription, reinforcing the court's view about prescription-based dispensing.

On the cumulative basis of (a) lack of visual and phonetic similarity, (b) regulatory and dispensing safeguards for Schedule H drugs, (c) absence of evidence of dishonest adoption, and (d) lack of prima facie evidence of confusion, the court concluded that the plaintiff did not make out a prima facie case nor show a strong likelihood of ultimate success necessary for interim relief.

Holding and Implications

I.A. dismissed.

Direct consequences: the interlocutory application for a temporary injunction was dismissed; the suit itself remained on the court's roll (directions were given for admission/denial of documents before the Deputy Registrar and for framing of issues on a later date). The opinion did not articulate any broader legal principle or seek to lay down a new precedent beyond applying the existing authorities to the facts; therefore, no new precedent was announced by this order and its immediate effect was to refuse interim relief to the plaintiff.

    E.R. Squibb & Sons Inc. v. Curewel India Ltd.

    H.C Goel, J. (Oral):— The plaintiff, E.R Squibb & Sons Inc. filed this suit against the defendant, Curewel (India) Ltd. for a permanent injunction against the defendant restraining it from selling in any manner its product under the brand name ‘Curechlor’ or any other deceptively mark similar to the registered trade mark of the plaintiff ‘Peclor’ with respect to the pharmaceutical preparation known as ‘Chloramphenicol’. Alongwith the suit the plaintiff filed this application under Order 39 Rules 1 and 2 and Section 151 of the Code of Civil Procedure with the same prayer for temporary injunction till the decision of the suit.

    The case of the plaintiff is that the plaintiff has been selling the said product under the trade mark ‘Reclor’ in India from the year 1971 to March 1, 1977 through the instrumentality of its registered users, Karamchand Premchand Pvt. Ltd. and Sarabhai Chemicals Ltd. and that from March 1, 1977 onwards till now the said product is being sold by its proposed registered users, Elscope Pvt. Ltd. It is alleged that the trade mark ‘Reclor’ with respect to the said substance was registered in favour of the plaintiff in India on May 4, 1966. This was registered with respect to medicinal and pharmaceutical preparations. The further allegations of the plaintiff are that in October 1984, the plaintiff came to know that the defendant had also been selling the medicine containing Chloramphenicol under the trade name ‘Curechlor’ in capsules. According to the plaintiff the defendant has appropriated the trade mark of the plaintiff and has added the letters ‘Cu’ in the beginning and has added the letter ‘h’ after ‘c’ of the trade mark ‘Reclor’ of the plaintiff and that the trade mark ‘Curechlor’ as adopted by the defendant is deceptively similar, visually and phonetically, with its trade mark ‘Reclor’. The plaintiff in paragraph 8 of the application made a specific averment, that the defendant's preparations ‘Curechlor’ is likely to be supplied mistakenly by the druggists and chemists when ‘Reclor’ is prescribed. It was further stated that it was quite possible that even a trained nurse might be misled into giving to a patient ‘Curechlor’ in place of ‘Reclor’.
    3. The question for consideration is as to whether the adoption of the trade mark ‘Curechlor’ by the defendant for its product containing the basic drug ‘Chloramphenicol’ amounts to inparations. The further allegations of the plaintiff are that Supreme Court in the case of F. Hoffiman-La Roche and Co. Ltd. v. Geoffrey Manners and Co. Private Ltd., AIR 1970 S.C 2062 (1) considered the question as to whether, the word ‘Dropovit’ was deceptively similar to the word ‘Protovit’, both of them being vitamin preparations. In this case F. Hoffimann-La Roche and Co. Ltd. had applied for rectification of the registration granted in favour of Geoffrey Manners and Co. Private Ltd. of the trade mark ‘Dropovit’ in respect of medicinal and pharmaceutical preparations and substances. The Supreme Court held that the question of deceptive similarity must be decided on the basis of class of goods to which the two trade marks applied. It was observed that from the nature of the goods it was ‘likely’ that most of the customers would obtain a prescription from a doctor and show the same to the chemist before the purchase. In such a case, except in the event of the handwriting of the doctor being very bad or illegible the chance of confusion was remote. The Supreme Court also on a comparison of the competing trade marks came to the conclusion that the trade mark ‘Dropovit’ was not deceptively similar to the trade mark ‘protovit’. Mr. L.C Goyle, learned counsel for the defendant, also cited a few English judgments relating to the cases of pharmaceutical preparations namely, Re: Bayer Products, Ltd's Application, (1947) 2 All. E.R 188, (2) Geigy A.G v. Chelsea Drug and Chemical Company Limited, (1966) RPC 64 (3) and Indo-Pharma Pharmaceutical Works Pvt. Ltd. v. Farbenfabreken Bayer Ag., (1975) RPC 545. (4) He also referred to the decision in the case of Stadmed Pvt. Ltd., Calcutta v. Hind Chemicals, Kanpur, AIR 1965 Punjab 17: (5) Mount Mettur Pharmaceuticals (P) Ltd. v. Dr. A. Wander AIR 1977 Madras 105 (6) and Chemical Industrial and Pharmaceutical Laboratories Ltd. v. A. Wulfing and another, (1979) 3 IPLR 193 (Bom. HC). (7) He also referred to para 671 of Narayanan on Trade Marks and Passing-Off (Third Edition). These judgments deal with cases of pharmaceutical preparations and a similar view has been taken in all these judgments as was taken by the Supreme Court in F. Hoffimann's case (supra) i.e that the question of deceptive similarity must be decided on the basis of class of goods to which the two trade marks applied. We have to judge the case of the plaintiff on the principal as stated above.
    4. The two trade marks in question are obviously not similar visually as the trade mark of the defendant starts with the letter ‘Cu’ preceding the entire trade mark ‘Reclor’ of the plaintiff. There is also an addition of the letter ‘h’ after the letter ‘c’ of ‘Reclor’. Phonetically also there is a distinct dissimilarity between the two trade marks ‘Reclor’ and ‘Chrechlor’. I do not agree with the submission of Mr. Anoop Singh that there is a great similarity in the two marks phonetically as suggested by him that the letter ‘cu’ which creates the distinction in the two marks phonetically may sometimes be spoken feebly or may not be quite audible to a person with whom an order is placed for the sale of ‘Reclor’. It is also worthnoting that the name of the defendant company is Curewel (India) Ltd. The defendant has filed its price list effective from July 1, 1985. This shows that the plaintiff has brand names for a number of its preparations starting with the word ‘Cure’ such as ‘Curecycline’, ‘Curemide’, ‘Curemox’, ‘Curifam’. ‘Curebutorl’. ‘Curepar’ and ‘Curedopa’. Nothing has been alleged by the plaintiff that the defendant has adopted the trade mark ‘Curechlor’ dishonestly with a view to trade on the trade mark ‘Reclor’ of the plaintiff. To the contrary the fact that the plaintiff's name is Curewel and a number of its products have the letters ‘Cure’ appended in the beginning to its brands goes to show that the adoption of the trade mark ‘Curechlor’ by the defendant for marketing ‘Cholramphenical’ which is the base drug, is a bona fide one. The defendant's counsel explained that the defendant has adopted the letters ‘Cure’ from its trading style and has adopted the word ‘chlor’ from the product itself just as the plaintiff has done for its mark ‘Reclor’ as is the common practice with the pharmaceutical companies preparation ‘Chloramphenicol’ which is being marketed by both the sides under the two brand names is admittedly a Schedule ‘H’ drug and as per sub-rule (9) (a) of Rule 65 of the Drugs and Cosmetics Rules, 1945 substances specified in Schedule H or Schedule X shall not be sold by retail except on and in accordance with the prescription of a Registered Medical Practitioner. The supply of drugs specified in Schedule H or Schedule X to Registered Medical Practitioners, Hospitals, Dispensaries and Nursing Homes can also be made only against the signed order in writing which has to be preserved by the licensee for a period of two years. There are conditions given for the purposes of preparation of prescriptions also with regard to the Schedule H drugs. Sub-rule (11) of Rule 65 says that persons dispensing a prescription containing a drug specified in Schedule H, like the drug in question, shall comply with requirements as detailed thereunder which also places a number of restrictions on the dispensing chemists for their sale to customers. The dispensing chemists also according to these rules have to be persons qualified in the Science of Pharmacology. Thus keeping in view these safeguards and restrictions regarding the stocking and sale to customers thereto by the chemists I am of the considered view that the chemists who alone are to sell the product in question to customers are not likely to be confused by the trade mark of the defendant when they have to sell the product of the plaintiff under the brand name ‘Reclor’. It may also be stated that the plaintiff has not placed any material whatsoever on the record to prima facie show, nor even alleged that any particular person whether an ordinary customer or a chemist was misled to take the product of the defendant as that of the plaintiff. The plaintiff has placed two cash memos on the record relating to the sale of the product or the defendant under the name ‘Curechlor. In both the cash memos the name of the patient as also the name of the doctor prescribing the same are duly given which showed that she preparation in question of the defendant is sold only on the prescription of a Medical Practitioner. Thus in view of what has been said above I am of the view that the plaintiff does not have a goods prima facie case and it does not have a good chance of ultimate success in the suit for the perpetual injunction as prayed for by it.
    5. Mr. Anoop Singh, learned counsel for the plaintiff, also cited a number of judgments in support of his contention that the trade mark ‘Curechlor’ is deceptively similar to the trade mark ‘Reclor’ in respect of medicinal preparations. It was pointed out that in the case of Kemp & Co. Ltd. v. Cadilla Laboratories Private Limited, (8) a photo copy of which judgment was placed on the record, an order allowing a temporary injunction in favour of Cadilla plaintiff/respondent, restraining the defendant/appellant from using the trade mark ‘Kempsillin’ in respect of the medicinal preparation was affirmed. In that case the plaintiff's registered trade mark was ‘Campicillin’. A perusal of the judgment shows that the ratio of the decision in that case was that there was 99 per cent phonetical similarity the two names. Such is not the position in the present case when we compare the two marks ‘Reclor’ and ‘Curechlor’. In standard Pharmaceuticals Limited v. U.P Drug Pvt. Ltd. 1980 IPLR 117, (9) the Lucknow Bench of the Allahabad High Court held that the trade mark ‘Winotone’ amounted to infringement of the trade mark ‘Vintone’ when both of them were in respect of medicinal preparations. There is obviously a great similarity phonetically in both these marks. Besides that the preparations in that case were mere tonics and were not Schedule ‘C’ or Schedule ‘H’ drugs so that they were to be dispensed by the chemists on a prescription of a Medical Practitioner only. This judgment is, therefore, distinguishable from the present case and is of no help to the case of the plaintiff.
    6. None of the other judgments as referred to by Mr. Anoop Singh relates to the case of medicinal and pharmaceutical preparations and they deal with general classes of consumer goods and they are not quite relevant for the purpose of the present case as the present case relates to the trade mark in relation to pharmaceutical preparations.
    7. In conclusion I find no merit in the application and the same is dismissed.
    Suit No. 2152/85
    The parties are directed to appear before the Deputy Registrar on March 18, 1986 for admission/denial of documents and the suit be listed before the Court on May 26, 1986 for framing of issues.
    I.A dismissed.
    Use AI to get other relevant cases.

    Comments

    E.R. Squibb & Sons Inc. v. Curewel India Ltd.
    (Feb 11, 1986)